News

Caldic announces partnership with BIO-CAT to bring innovative probiotics to the Companion Animal Health and Nutrition industry

BIO-CAT, Inc., an industry leading probiotic manufacturer, has agreed to partner with global distribution solutions provider Caldic North America to bring their proprietary probiotic strains and OPTIFEED® branded solutions to the Companion Animal Health and Nutrition market in North America. This agreement secures a rapid go-to-market strategy for BIO-CAT, leveraging Caldic’s leadership position in the Companion Animal market as a provider of value-add antioxidant, vitamin, mineral, and ingredient solutions.

Founded in Keswick, Virginia, BIO-CAT is an industry-leading expert in specialty enzyme and probiotic formulations. The company offers an extensive range of single-to-multi-enzyme blends and unique microbial solutions for better animal digestive health. BIO-CAT Microbials, located in Shakopee Minnesota, is BIO-CAT’s vertically integrated FDA registered and SQF certified (human-grade) U.S. fermentation facility. Their AAFCO-listed OPTIFEED® probiotic strains are premium, safe, effective, and have shown physiological benefits to companion animals in support of their gastrointestinal and digestive health; similar to the benefits they deliver to humans. Future expansion of the OPTIFEED® line of enzymes will further support digestive health, enhancing the nutritional value of pet food, and can be used in ingredient processing and flavor development.

“This partnership with BIO-CAT significantly strengthens Caldic’s existing Companion Animal portfolio,” says Liz Parker, Director of Companion Animal Health & Nutrition, Caldic North America, “adding a range of innovative and customizable solutions to inspire quality pet food and health. As the importance of pet companionship is widely recognized, domestic animal owners are increasingly keen to provide their pets with nutritionally high-performing food, treats and supplements. The expert know-how our R&D team has acquired in pet food when formulating with our antioxidants range, Dadex®, and our custom vitamin and mineral blends, Daminaide®, will greatly benefit the solutions we can deliver across North America while partnering with BIO-CAT.”

“BIO-CAT Microbials’ expertise in probiotic strain development and fermentation is a great match for Caldic’s exceptional distribution solutions,” says Chris Schuler, President and CEO of BIO-CAT. “We value Caldic’s commitment to the Companion Animal space and their ability to scale our OPTIFEED® probiotic business within their customer base. We look forward to a successful collaboration and exclusive partnership with Caldic.”

Recent News

10/29/2026

ReAlta Life Sciences Launches KnowHIE, a New Online Educational Resource for Families of Babies Diagnosed with Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the launch of KnowHIE.com, a new educational website designed to help families and caregivers better understand neonatal hypoxic ischemic encephalopathy (HIE) …

10/28/2026

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a biopharmaceutical company developing treatments for serious inflammatory diseases, today announced that it has changed its corporate name to Azora Therapeutics, Inc. The company’s common stock is expected to commence trading on The Nasdaq Capital Market under the new ticker symbol “AZR” on October 29, 2026. Azora has also launched …

10/28/2026

U.S. Bioscience Industry Powers Over $3 Trillion in Economic Output, New Report Finds

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact. The report, “The U.S. Bioscience Economy: Advancing Innovation and Strengthening States and Regions,” examines the industry’s economic footprint through employment, wages, business establishments, university research and development, access …